Announcement on the waiver of the preemptive right of equity of subsidiaries
Release time:
2020-08-05
证券代码：600668 证券简称：尖峰集团 公告编号：2019-030
债券简称：13尖峰02 债券代码：122344
浙江尖峰集团股份有限公司
关于放弃子公司股权优先购买权的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示：
l 简要内容：近日，浙江尖峰集团股份有限公司（以下简称“本公司”）与本公司控股子公司浙江尖峰水泥有限公司（以下简称“尖峰水泥”）收到中国建材股份有限公司（以下简称“中建股份”）《通知书》，中建股份拟将其所持有的本公司控股子公司大冶尖峰水泥有限公司（以下简称“大冶尖峰”）24%股权划转给其全资子公司中建材投资有限公司（以下简称“中建投资”），以增加中建投资的注册资本。本次划转以经审计的大冶尖峰2019年5月31日的所有者权益账面值为依据作价11,032.82万元。划转后中建投资将持有大冶尖峰24%的股权。本公司同意上述股权划转事宜并放弃该部分股权的优先购买权。
l 本事项不构成关联交易
l 本事项不构成重大资产重组
l 本事项需经公司董事会审议,不需提交股东大会审议批准。
一、 基本概述
（一）近日，本公司与本公司控股子公司尖峰水泥收到中建股份《通知书》，中建股份拟将其所持有的本公司控股子公司大冶尖峰24%股权划转给其全资子公司中建投资，以增加中建投资的注册资本。本次划转以经审计的大冶尖峰2019年5月31日的所有者权益账面值为依据作价11,032.82万元。划转后中建投资将持有大冶尖峰24%的股权。
中建投资系中建股份的全资子公司，本次大冶尖峰股权变动是中建股份的内部股权划转，划转后该部分股权的实际控制权不变。本公司同意上述划转事宜并放弃该部分股权的优先购买权。该事宜不构成关联交易，也不构成重大资产重组。
（二）董事会审议情况
2019年8月29日，公司以通讯方式召开了第十届董事会第11次会议，公司现有八名董事，全部参加了会议，经审议与表决，董事会以8票同意、0票反对、0票弃权审议并通过了该事项。
（三）根据上海证券交易所《股票上市规则》和公司《章程》等有关规定，该事项属董事会权限范围，无需提交股东大会审议。
二、 标的公司的基本情况
（一）基本情况
1、企业名称：大冶尖峰水泥有限公司
2、企业类型：其他有限责任公司
3、注册地：湖北省大冶市保安镇
4、注册日期：2003年12月24日
5、主要办公地点：湖北省大冶市保安镇
6、法定代表人：蒋晓萌
7、注册资本：25000万元
8、经营范围：水泥、水泥熟料、水泥机电设备制造及销售,建材产品销售,水泥配料用石灰石、砂页岩开采及销售,水泥炉窑固体废物、危险废物协同处置。(涉及许可经营项目,应取得相关部门许可后方可经营)
9、主要股东
|
序号 |
股东姓名 |
出资（万元） |
持股比例（%） |
|
1 |
尖峰水泥 |
17500 |
70.00 |
|
2 |
中建股份 |
6000 |
24.00 |
|
3 |
本公司 |
1500 |
6.00 |
|
合计 |
25000 |
100.00 |
|
注：尖峰水泥是本公司的控股子公司，本公司持有尖峰水泥95.25%的股权。
10、划转前后大冶尖峰股权结构对比
划转前 划转后
（二）大冶尖峰的主要财务数据
单位：万元
|
项目 |
2018.12.31 |
2019.05.31 |
|
总资产 |
71,623.22 |
63,439.15 |
|
总负债 |
19,320.36 |
17,469.08 |
|
所有者权益 |
52,302.86 |
45,970.07 |
|
|
2018年度 |
2019年1-5月 |
|
营业收入 |
94,949.57 |
36,397.38 |
|
利润总额 |
37,358.53 |
14,340.63 |
|
净利润 |
27,901.21 |
10,667.20 |
大冶尖峰2018年度和2019年1-5月的财务数据经具有证券、期货从业资格的天健会计师事务所（特殊普通合伙）审计。
三、 划转各方的基本情况
（一）股权划出方的基本情况
1、企业名称：中国建材股份有限公司
2、企业类型：股份有限公司（上市、国有控股）
3、注册地：北京市海淀区复兴路17号国海广场2号楼（B座）
4、注册日期：1985年06月24日
5、主要办公地点：北京市海淀区复兴路17号国海广场2号楼（B座）
6、法定代表人：曹江林
7、注册资本：843,477.0662万元
8、经营范围：对外派遣与其实力、规模、业绩相适应的境外工程所需的劳务人员；新型建筑材料及制品、新型房屋、水泥及制品、玻璃纤维及制品、复合材料及制品的技术研发、生产和销售；建筑材料的仓储、配送和分销：水泥、玻璃生产线的技术研发、工程设计与工程总承包；新型建筑材料的工程设计与工程总承包；与以上业务相关的技术咨询、信息服务；承包境外建材、建筑和轻纺行业的工程勘测、咨询、设计和监理及工程；进出口业务。( 企业依法自主选择经营项目，开展经营活动；依法须经批准的项目，经相关部门批准后依批准的内容开展经营活动；不得从事木市产业政策禁止和限制类项目的经营活动。)
（二）股权划入方的基本情况
1、企业名称：中建材投资有限公司
2、企业类型：有限责任公司（法人独资）
3、注册地：深圳市罗湖区人民南路国贸大厦12楼南
4、注册日期：2001年01月08日
5、主要办公地点：深圳市罗湖区人民南路国贸大厦12楼南
6、法定代表人：蔡国斌
7、注册资本：300,000万元
8、经营范围：投资兴办实业(具体项目另行申报)；从事物流业务(外商投资准入负面清单类除外)；电子商务服务(不含增值电信业务)；国内贸易；经营进出口业务；在合法取得使用权的土地上从事房地产开发经营(外商投资准入负面清单类除外,具体项目另行申报)；物业租赁。(企业经营涉及前置性行政许可的,须取得前置性行政许可文件后方可经营)煤炭经营。
四、 对本公司的影响
中建投资系中建股份的全资子公司，本次划转系中建股份为了进一步优化组织结构、增强中建投资的实力而进行的内部股权划转。本次股权划转后，中建投资将持有大冶尖峰24%的股权，该部分股权的实际控制权不变。本公司与尖峰水泥所持大冶尖峰比例不变，大冶尖峰仍受本公司实际控制，本公司同意放弃该部分股权的优先购买权不存在损害公司及股东特别是中小股东利益的情形。
特此公告
浙江尖峰集团股份有限公司
董事会
二〇一九年八月三十一日
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page